Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Cell Death and Differentiation|August 23, 2014
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesisJu Liu, C Zhang, X L Wang, et al.Journal of Internal Medicine|April 17, 2015
Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic diseaseS Brauner, W Zhou, C Backlin, et al.Journal of Clinical Pathology|June 19, 2013
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphomaE Frei, C Visco, Z Y Xu-Monette, et al.Leukemia|July 11, 2017
Targeting nucleolin for better survival in diffuse large B-cell lymphomaN Jain, H Zhu, T Khashab, et al.Leukemia|July 27, 2017
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapyZ Yao, L Deng, Z Y Xu-Monette, et al.Leukemia|August 27, 2015
Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL ConsortiumL Deng, Z Y Xu-Monette, S Loghavi, et al.Leukemia|August 30, 2016
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphomaY Xia, Z Y Xu-Monette, A Tzankov, et al.Leukemia|March 23, 2012
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyC Visco, Y Li, Z Y Xu-Monette, et al.Pageof 1